Theraclion

Theraclion is a French medical device company based in Malakoff, in the Paris region, that designs and markets robotic, fully non-invasive platforms based on High-Intensity Focused Ultrasound (HIFU), a technology the company brands as 'echotherapy'. Its mission, stated on its website, is to develop non-invasive, intelligent, robotic platforms that reduce healthcare system and human costs and unleash treatment opportunities. The company's two commercial product lines are SONOVEIN, dedicated to the non-invasive treatment of varicose veins, and ECHOPULSE, dedicated to the non-invasive treatment of thyroid nodules and breast fibroadenoma. Both platforms are operated with a single-use patented disposable called EPack, which provides acoustic coupling and skin cooling. Theraclion's research phase began in 2004. The first ECHOPULSE system, treating thyroid nodules and breast fibroadenoma, was delivered in 2014. In 2017 the company started a collaboration with the University of Virginia Cancer Center in the United States in breast cancer research. SONOVEIN, its first varicose veins robotic platform, was launched in 2019, and the upgraded SONOVEIN HD was launched in 2022. By 2024, SONOVEIN was present in more than 15 countries across Europe, China and the United States. The company reports that more than 4,000 patients have been treated, that its devices hold CE Mark under MDR, that its centers operate in more than 10 countries, and that SONOVEIN achieved 96.8% efficacy in an FDA pivotal trial. SONOVEIN is positioned as the first and only robotic solution for the non-invasive echotherapy treatment of varicose veins. It requires no additional accessories such as guide wires, puncture kits or catheters, can be operated by a single person in a non-sterile environment, and needs no wake-up rooms or hospital beds. Because there are no incisions and no scars, patients can resume normal daily activities immediately after treatment. The newest version, SONOVEIN HD, incorporates leading-edge imaging capabilities from SuperSonic Imagine. ECHOPULSE is a completely non-invasive robot for echotherapy treatment of thyroid nodules and breast fibroadenoma that can be operated by a single person in a standard physician's office; it leaves no scars and maintains thyroid function and the integrity of breast tissue. Theraclion is headquartered in Malakoff, Paris, France, and its management team includes Martin Deterre as Chief Executive Officer, Julie Veisseire as Chief Financial Officer, Michel Nuta as VP Veins & Chief Medical Officer, Jérémie Anquez as VP Research & Chief Scientific Officer, Alexandra Rocher as VP Operations, Vivien Jourdannaud as VP Regulatory Affairs and Thibault Le Normand as Chief Business Officer. The board is presided over by Vincent Gardès and includes Claude Lenoir, Lijuan Deng and Cédric Bellanger. The company is listed on Euronext Growth Paris under the ticker ALTHE.

Theraclion's history begins with a research phase that started in 2004, according to the company's own account. The company was founded in Malakoff, in the Paris region of France, and built its technology around High-Intensity Focused Ultrasound (HIFU), which it markets under the name 'echotherapy'. HIFU works like a magnifying glass, concentrating ultrasound waves to a focal point so that tissue can be treated without incisions; the main advantage for the patient is that the procedure is non-invasive and therefore does not require a sterile environment like an operating room. In 2014, the first ECHOPULSE system was delivered. ECHOPULSE is a completely non-invasive robot for the echotherapy treatment of thyroid nodules and breast fibroadenoma. It can be operated by a single person in a standard physician's office, leaves no scars, and is designed to maintain thyroid function and the integrity of breast tissue. In 2017, Theraclion began a collaboration with the University of Virginia Cancer Center in the United States in breast cancer research, extending its clinical research footprint into the U.S. In 2019, Theraclion launched SONOVEIN, its first robotic platform for varicose veins. SONOVEIN is described as the first and only robotic solution for the non-invasive echotherapy treatment of varicose veins. It requires no additional accessories such as guide wires, puncture kits or catheters, can be operated by a single person in a non-sterile environment, and needs no wake-up rooms or hospital beds. From a histological perspective, vein ablation by echotherapy with SONOVEIN and radiofrequency display identical features, with the significant benefit of echotherapy being completely non-invasive: the high-intensity ultrasound beam is focused on the vein while a standard ultrasound beam controls accuracy, and as thermal energy is delivered the vein shrinks and is sealed closed, similar to other endothermal methods but without incisions. In 2022, Theraclion launched SONOVEIN HD, the newest version of the platform, which includes leading-edge imaging capabilities from SuperSonic Imagine. By 2024, SONOVEIN was present in more than 15 countries across Europe, China and the United States. The company reports that more than 4,000 patients have been treated, that its devices hold CE Mark under MDR, that its centers operate in more than 10 countries, and that SONOVEIN achieved 96.8% efficacy in an FDA pivotal trial. Both SONOVEIN and ECHOPULSE operate with a single-use patented disposable, the EPack, which ensures cooling and coupling functions; it is installed on the device before each treatment and protects the patient's skin while optimizing image quality. EPack is a class I medical device under Directive 93/42/EEC, designed and marketed by Theraclion, and has received CE-mark to support treatments performed with Theraclion's echotherapy devices. Theraclion is headquartered in Malakoff, Paris, France, and is listed on Euronext Growth Paris under the ticker ALTHE. Its management team includes Martin Deterre as Chief Executive Officer, Julie Veisseire as Chief Financial Officer, Michel Nuta as VP Veins & Chief Medical Officer, Jérémie Anquez as VP Research & Chief Scientific Officer, Alexandra Rocher as VP Operations, Vivien Jourdannaud as VP Regulatory Affairs and Thibault Le Normand as Chief Business Officer. The board is presided over by Vincent Gardès and includes Claude Lenoir, Lijuan Deng and Cédric Bellanger.

• 2024

  SONOVEIN is present in more than 15 countries (Europe, China, USA).

• 2022

  SONOVEIN HD is launched.

• 2019

  SONOVEIN, the first varicose veins robotic platform, is launched.

• 2017

  Start of collaboration with the University of Virginia Cancer Center (US) in breast cancer research.

• 2014

  First ECHOPULSE system, treating thyroid nodules and breast fibroadenoma, is delivered.

• 2004

  Research phase begins.

Pioneer of robotic, fully non-invasive HIFU 'echotherapy' platforms for vein care and office-based treatment of thyroid nodules and breast fibroadenoma.

• SONOVEIN

  First and only robotic solution for the non-invasive echotherapy treatment of varicose veins; no incisions, no sedation, no tumescence; can be operated by a single person in a non-sterile environment.

• SONOVEIN HD

  Newest version of SONOVEIN, including leading-edge imaging capabilities from SuperSonic Imagine.

• ECHOPULSE

  Completely non-invasive robot for echotherapy treatment of thyroid nodules and breast fibroadenoma; can be operated by a single person in a standard physician's office; leaves no scars and maintains thyroid function and breast tissue integrity.

• EPack

  Single-use patented disposable ensuring cooling and coupling functions for SONOVEIN and ECHOPULSE; class I medical device under Directive 93/42/EEC, CE-marked.

1. 1Theraclion - Focused Ultrasound Medical Device Companytheraclion.com
2. 2About us - Theracliontheraclion.com
3. 3EPack - Theracliontheraclion.com
4. 4SONOVEIN ® - Medical Device Treating Varicose Veinstheraclion.com
5. 5Theraclion (France) - Wikidatawikidata.org